CN112933249A - 一种pd-l1靶向双模态分子探针及其制备方法和应用 - Google Patents
一种pd-l1靶向双模态分子探针及其制备方法和应用 Download PDFInfo
- Publication number
- CN112933249A CN112933249A CN202110327819.9A CN202110327819A CN112933249A CN 112933249 A CN112933249 A CN 112933249A CN 202110327819 A CN202110327819 A CN 202110327819A CN 112933249 A CN112933249 A CN 112933249A
- Authority
- CN
- China
- Prior art keywords
- dota
- icg
- molecular probe
- polypeptide
- ntyyedqg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008096 B7-H1 Antigen Human genes 0.000 title claims abstract description 79
- 108010074708 B7-H1 Antigen Proteins 0.000 title claims abstract description 79
- 239000003068 molecular probe Substances 0.000 title claims abstract description 47
- 230000002902 bimodal effect Effects 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 229920001184 polypeptide Polymers 0.000 claims abstract description 53
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 53
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 52
- 238000001514 detection method Methods 0.000 claims abstract description 24
- 238000002372 labelling Methods 0.000 claims abstract description 8
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims abstract description 6
- 229960004657 indocyanine green Drugs 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 48
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 40
- 238000011282 treatment Methods 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 239000000523 sample Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000003745 diagnosis Methods 0.000 claims description 11
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 11
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 10
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 8
- 239000012216 imaging agent Substances 0.000 claims description 8
- 239000002738 chelating agent Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 230000001588 bifunctional effect Effects 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 238000001819 mass spectrum Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 230000002285 radioactive effect Effects 0.000 claims description 5
- 239000007790 solid phase Substances 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 238000010511 deprotection reaction Methods 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 229910052733 gallium Inorganic materials 0.000 claims description 3
- 229910052732 germanium Inorganic materials 0.000 claims description 3
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 239000000412 dendrimer Substances 0.000 claims description 2
- 229920000736 dendritic polymer Polymers 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 abstract description 14
- 230000008685 targeting Effects 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 5
- 210000004881 tumor cell Anatomy 0.000 abstract description 5
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 4
- 230000005847 immunogenicity Effects 0.000 abstract description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 230000008878 coupling Effects 0.000 description 17
- 238000010168 coupling process Methods 0.000 description 17
- 238000005859 coupling reaction Methods 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 238000003384 imaging method Methods 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 10
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000799 fluorescence microscopy Methods 0.000 description 6
- 238000004393 prognosis Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 238000012636 positron electron tomography Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229940125644 antibody drug Drugs 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- HBGPNLPABVUVKZ-POTXQNELSA-N (1r,3as,4s,5ar,5br,7r,7ar,11ar,11br,13as,13br)-4,7-dihydroxy-3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-2,3,4,5,6,7,7a,10,11,11b,12,13,13a,13b-tetradecahydro-1h-cyclopenta[a]chrysen-9-one Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@@H]1[C@H](O)C[C@]([C@]1(C)C[C@@H]3O)(C)[C@@H]2CC[C@H]1[C@@H]1[C@]3(C)CC[C@H]1C(=C)C HBGPNLPABVUVKZ-POTXQNELSA-N 0.000 description 1
- PFRGGOIBYLYVKM-UHFFFAOYSA-N 15alpha-hydroxylup-20(29)-en-3-one Natural products CC(=C)C1CCC2(C)CC(O)C3(C)C(CCC4C5(C)CCC(=O)C(C)(C)C5CCC34C)C12 PFRGGOIBYLYVKM-UHFFFAOYSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- KZYSHAMXEBPJBD-JRQIVUDYSA-N Asn-Thr-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KZYSHAMXEBPJBD-JRQIVUDYSA-N 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- SOKRNBGSNZXYIO-UHFFFAOYSA-N Resinone Natural products CC(=C)C1CCC2(C)C(O)CC3(C)C(CCC4C5(C)CCC(=O)C(C)(C)C5CCC34C)C12 SOKRNBGSNZXYIO-UHFFFAOYSA-N 0.000 description 1
- HKYTWJOWZTWBQB-AVGNSLFASA-N Tyr-Glu-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HKYTWJOWZTWBQB-AVGNSLFASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 231100001158 immune-related toxicity Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- -1 tetramethyluronium Hexafluorophosphate Chemical compound 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及医学检测技术领域,具体涉及一种PD‑L1靶向双模态分子探针及其制备方法和应用。本发明的PD‑L1靶向双模态分子探针为同时由吲哚菁绿ICG和正电子放射性核素68Ga标记的多肽,所述多肽的序列如SEQ ID NO.1所示。该双模态分子探针具有较高的标记率和稳定性,具有PD‑L1靶向特异性,选择性强、纯度高、分子量小、特异性强、无免疫原性、安全可靠,可用于检测肿瘤细胞中PD‑L1的表达情况,适于作为基于PD‑L1免疫治疗的预测和伴随诊断试剂。本发明提供的分子探针的制备方法具有简单易行、成本低廉的优势,实用性强,且具有良好生物安全性和较好的应用价值。
Description
技术领域
本发明涉及医学检测技术领域,具体涉及一种PD-L1靶向双模态分子探针及其制备方法和应用。
背景技术
目前,随着对肿瘤免疫逃逸机制研究的不断深入,针对免疫检查点的抑制剂在多种实体瘤的治疗中表现出了较好的临床效果,成为癌症治疗史上里程碑式的事件,使人们认识到免疫治疗能够真正成为恶性肿瘤治疗的重要角色。其中PD-1/PD-L1的抑制更受关注,目前FDA已经批准的PD-1抗体和PD-L1抗体在治疗黑色素瘤、胶质母细胞瘤的临床疗效上也很突出,这些抗体药物具有很高的亲和性和特异性,然而抗体药物存在的缺陷是无法忽略的,包括成本高、免疫相关毒性、药代动力学和肿瘤渗透不足等,这些因素阻碍了抗体类药物更广泛的临床应用。因此,探寻合适的疗效预测标志物,进而精准的选择出免疫治疗潜在的获益人群成为研究的热点。准确预测肿瘤对PD-1/PD-L1阻断剂的反应依然是个挑战。
PD-L1在肿瘤细胞或肿瘤基质的表达已经被建议作为PD-1或PD-L1定向免疫治疗反应预测的潜在疗效预测标志物。但目前对PD-L1表达的检测尚未得到统一的国际标准,而且多方面因素导致了单一的PD-L1表达水平作为疗效预测物的不可靠性。研究PD-L1在不同肿瘤的表达情况以及其与患者临床病理参数、预后的相关性,可为不同肿瘤的免疫治疗提供治疗及预后相关的临床参考和依据。二者与肿瘤的密切关系决定了其是当前肿瘤诊断和免疫治疗的热门分子靶标之一,其表达水平也是肿瘤预后的指标之一。到目前为止,通过手术切除肿瘤或组织活检等有创技术来检测PD-1和PD-L1的表达程度,由于用于检测抗体的品牌、检测技术、检测时的环境条件以及判定PD-L1阳性的cutoff值的不同均可导致检测结果的不一致。由于活检程序的相关风险和免疫组织化学(IHC)的缺陷,肿瘤异质性空间表达导致PD-L1表达的不敏感和肿瘤取样不完全等因素可能导致PD-L1检测出现假阳性。此外,获取样本时患者可处于基线或其他各线治疗状态,这也是造成检测结果差异的原因之一。这些因素不但影响了对PD-L1表达水平检测的一致性,同时也会影响其检测的可靠性和可重复性。除此之外,PD-L1表达水平的动态变化也是影响判定PD-L1确切的表达状态因素之一。因此,常规检测方法如免疫组织化学(IHC)方法、原位免疫杂交技术(FISH)等来预测抗PD-1/抗-PD-L1免疫治疗效果存在一定的片面性和局限性。随着癌症免疫疗法的不断发展,需要通过分子分型优化个体患者的治疗方法,并开发非侵入性分子影像工具,最终实现对临床免疫检查点封锁的动态监测。因此,快捷、简便、动态准确识别肿瘤细胞表面PD-L1蛋白表达水平的方法对肿瘤的诊断、免疫治疗及预后评估有着重要的意义。
目前,在肿瘤临床治疗过程中或治疗后,无创的、可重复性、高准确性地检测肿瘤PD-1和PD-L1的表达水平及活性尚难以实现,因而迫切需要特异性的影像检测技术来指导肿瘤治疗。分子影像在免疫治疗和个性化医学中发挥越来越重要的作用。其中分子探针的制备是分子影像的关键,只有高灵敏度和特异性的分子探针引入体内后可与细胞内特定的靶分子发生特异性结合并产生某种信号,体外通过特定的影像设备,如:正电子发射计算机断层扫描(PET-CT)、单光子发射计算机断层成像术(SPECT)、磁共振成像(MRI)以及荧光成像等进行采集成像,从而达到特异性诊断的才能实现高度特异性的诊断。
核医学分子示踪技术为肿瘤的早期诊断和预后提供了很好的手段,利用放射性分子探针可以无创地检测及评估肿瘤PD-L1表达水平,提供机体整体与远处转移时PD-1与PD-L1表达信息,避免了病理切片及治疗手段对机体PD-1与PD-L1表达水平的影响,为筛选PD-1/PD-L1免疫治疗有疗效响应的患者、优化肿瘤抗PD-1/抗PD-L1治疗方案、评估预后提供了新策略。
但由于抗体药物存在着制备繁琐、体外稳定性较差、分子较大、标记困难、穿透力弱,翻译后修饰且费用昂贵等原因使其进一步应用受到限制。因此,为了提高癌症诊断和治疗的特异性和准确性,弥补抗体的缺陷,迫切需要寻求针对新的肿瘤标志物设计小分子探针,以作为检测和治疗癌症的有效方法。因此,开发一种针对PD-1/PD-L1的小分子探针对PD-L1高表达的多种肿瘤的诊断将有突破性的重大意义。多肽类靶向小分子药物及诊断探针以成本低、分子量小、生物相容性好、穿透性强、无免疫原性、并有较快的血液清除速率、且制备简单等特点,在肿瘤靶向给药、癌症诊断等方面彰显出很强的优越性,甚至显示了替代抗体类诊疗试剂的趋势。因此,在癌症研究中针对肿瘤标志物合理设计并筛选对癌细胞的高特异亲和多肽,继而发展成为肿瘤的诊断试剂及治疗药物,是解决上述难题的有效途径。采用非侵入性方法可对整个肿瘤和相关转移灶同时成像,其可能与PD-L1表达状态中的原发性肿瘤不同,具有IHC无可比拟的优势,也不需要切除任何组织。由于靶向多肽其对PD-L1的高亲和力和特异性以及其增强的组织穿透,因此放射性标记的PD-L1靶向多肽可用作评估肿瘤PD-L1表达的有效分子探针而且更易进行临床转化。
发明内容
本发明的目的是提供一种PD-L1靶向双模态分子探针,该分子探针为PET和荧光双模态多肽探针。本发明还提供该分子探针的制备方法和应用。
具体地,本发明提供以下技术方案:
第一方面,本发明提供一种PD-L1靶向双模态分子探针,其为同时由吲哚菁绿ICG和正电子放射性核素68Ga标记的多肽,所述多肽的序列如SEQ ID NO.1所示。本发明发现,序列如SEQ ID NO.1所示的多肽能够特异性结合PD-L1,具有较高的亲和性,针对该多肽,在众多的标记物中,吲哚菁绿ICG和正电子放射性核素68Ga标记该多肽具有更高的稳定性和标记率,且不影响多肽的PD-L1靶向性,以吲哚菁绿ICG和正电子放射性核素68Ga标记该多肽得到的双模态分子探针的选择性和特异性更强,能够同时进行PET和近红外荧光成像技术检测,与其他标记的多肽探针相比,能够更好地检测PD-L1的表达。
优选地,所述ICG和68Ga分别通过双功能螯合剂DOTA与所述多肽连接。本发明选择双功能螯合剂DOTA作为分子探针的多肽与标记物之间的连接物,得到的双模态分子探针的稳定性和标记率显著提高,且不影响多肽的PD-L1靶向性,能够同时进行PET和近红外荧光成像技术检测,与其他标记的多肽探针相比,能够更好地检测PD-L1的表达。
其中,ICG通过巯基与DOTA偶连。
优选地,所述ICG通过双功能螯合剂DOTA与所述多肽连接得到的分子结构如式(I)所示:
在上述分子探针的基础上,本发明还提供所述分子探针的衍生物,所述衍生物为所述双模态分子探针的二价体或多价体,且能够特异性结合PD-L1;所述二价体或多价体为二个或多个所述双模态分子探针通过连接分子共价连接形成,或者,通过与多聚体混合、非共价连接形成。上述衍生物同样具有所述双模态分子探针的功能,能够同时进行PET和荧光成像检测PD-L1的表达。
优选地,所述的连接分子为2-S-(4-氨基苯)-1,4,7三氮杂环壬烷-1,4,7-三乙酸(NOTA)、1-乙基-3-(3-二甲基氨丙基)-碳化二亚胺(EDC)或N-羟基琥珀酰亚胺(NHS)。所述多聚体为聚乙二醇(PEG)、聚乙烯醇(PVA)、环糊精、聚酰胺-胺型树枝状高分子(PAMAM)、聚乳酸(PLA)、聚乳酸-乙醇胺(PLGA)中的任意一种或至少两种的组合。
第二方面,本发明提供所述PD-L1靶向双模态分子探针或其衍生物在制备药物中的应用。
以上所述的药物优选为用于PD-L1阳性肿瘤的预防、诊断或治疗的药物。
进一步优选地,所述药物用于PD-L1阳性肿瘤显像诊断或手术导航精准切除的检测。
本发明所述的PD-L1阳性肿瘤可为PD-L1蛋白过表达的所有肿瘤。
优选地,所述PD-L1阳性肿瘤为选自黑色素瘤、非小细胞肺癌、肾癌、前列腺癌、结直肠癌、胰腺癌、肝癌、胃癌、食道癌和乳腺癌中的任意一种。
第三方面,本发明提供一种药物,其包括所述PD-L1靶向双模态分子探针或其衍生物。
可选地,所述药物还包括显像制剂。
优选地,所述药物中,所述双模态分子探针、其二价体或多价体与所述显像制剂相缀合或混合。
进一步优选地,所述的显像制剂为放射性核素、放射性核素标记物、磁共振造影剂、分子影像制剂中的任意一种。
可选地,所述药物还可包含载体(纳米材料、脂质体等高分子材料)。所述药物中,所述双模态分子探针、其二价体或多价体与所述载体相缀合或混合。
第四方面,本发明提供所述PD-L1靶向双模态分子探针的制备方法,该方法包括如下步骤:将序列如SEQ ID NO.1所示的多肽与DOTA连接,得到PDP线性多肽;将所述PDP线性多肽进行ICG标记后,再进行68Ga标记。
优选地,PD-L1靶向双模态分子探针的制备方法包括如下步骤:
(1)CK(DOTA)NTYYEDQG的制备
先通过Fmoc固相合成Fmoc-CK(Dde)NTYYEDQG,用2%水合肼将K的侧链保护基Dde脱掉暴露氨基后,将DOTA和Fmoc-CKNTYYEDQG多肽溶于DMF中,用DIEA调节pH值至8.5-9.0,室温搅拌过夜;加入20%哌啶脱保护,室温反应10分钟;得到的产品经C18半制备柱HPLC分离纯化,得到PDP线性多肽CK(DOTA)NTYYEDQG;
(2)ICG-CK(DOTA)NTYYEDQG的制备
将1mg CK(DOTA)NTYYEDQG多肽溶于1×PBS中,0.5mg ICG-MAL溶于500μL去离子水中,将二者混合调pH至7.4,室温振荡反应24h,冷冻干燥后进行质谱检测和HPLC纯化;
(3)ICG-CK(68Ga-DOTA)NTYYEDQG的制备
将ICG-CK(DOTA)NTYYEDQG溶于去离子水中;用5mL 0.1mol/L高纯度盐酸溶液淋洗锗镓68Ge/68Ga发生器,收集其中放射性含量最高的1mL,加入醋酸钠将混合液pH值调至3.5-4.5;将30μg前体ICG-CK(DOTA)NTYYEDQG加入至混合液中并充分混匀,加热至100℃保持10min;得到ICG-CK(68Ga-DOTA)NTYYEDQG。
本发明针对序列如SEQ ID NO.1所示的多肽以及标记物的结构和性质特点开发了相适应的制备方法,上述制备方法能够保证本发明的双模态分子探针的高效、高纯度合成,标记率可达99.00%,且制备方法简单易行,成本低廉。
本发明的有益效果在于:本发明提供了一种靶向PD-L1的新型双模态多肽探针,该探针包括PDP多肽以及放射性核素68Ga和吲哚菁绿ICG,其中,PDP多肽是将多肽NTYYEDQG与功能螯合剂DOTA连接;放射性核素68Ga通过双功能螯合剂DOTA标记多肽,ICG-MAL通过巯基与DOTA偶连。本发明所提供的放射性核素68Ga标记的PD-L1靶向多肽的标记率可达99.00%,稳定性好,具有PD-L1靶向特异性,选择性强、纯度高、分子量小、特异性强、无免疫原性、安全可靠,可用于检测肿瘤细胞中PD-L1的表达情况,适于作为基于PD-L1免疫治疗的预测和伴随诊断试剂,以实时监控免疫治疗的疗效及其相应的受益患者筛选,为多种肿瘤的早期诊断和免疫治疗中检查点的动态监测等提供重要的理论和临床参考依据。
基于单抗的分子探针存在明显不足(分子量大、易失活、组织渗透慢、血液清除慢等),而本发明提供的基于多肽的分子探针在保持良好靶向性基础上,能克服上述不足,具有显著优势。此外,PET在临床中普及度最高,因此,本发明的分子探针有利于后期临床转化,可以全面显示肿瘤区域以及转移灶的PD-L1表达水平,可在整个治疗过程中监测PD-L1水平的动态变化,而无需重复有创的取组织做活检。PD-L1生物标志物的鉴定有利于医生制定个性化治疗方案以取得最优的治疗效果,具有较好的研究前景和临床指导意义。
本发明提供的分子探针的制备方法具有简单易行、成本低廉的优势,实用性强,且具有良好生物安全性和较好的应用价值。
附图说明
图1为本发明实施例1中CK(DOTA)NTYYEDQG的质谱图。
图2为本发明实施例1中CK(DOTA)NTYYEDQG的液相色谱图。
图3为本发明实施例2中ICG-CK(DOTA)NTYYEDQG的质谱图。
图4为本发明实施例3中68Ga-DOTA-NTYYEDQG的液相色谱图。
图5为本发明实施例4中ICG-CK(DOTA)NTYYEDQG的小鼠近红外荧光成像。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。
实施例1 PD-L1靶向双模态分子探针的合成
1、实验仪器与材料
N-甲基吗啉(NMM),哌啶,三氟乙酸(TFA),二氯甲烷(DCM),茚三酮,维生素C,苯酚,四甲基脲六氟磷酸盐(HBTU),六氢吡啶,三异丙基硅烷(TIS),乙二硫醇(EDT),N,N二甲基甲酰胺(DMF),无水乙醚,树脂,甲醇,各种Fmoc保护氨基酸,多肽合成管,摇床,真空水泵,旋转蒸发仪,上述试剂和材料均从商业途径获得。
2、PD-L1靶向多肽的合成
采用Fmoc固相肽合成方法合成多肽,具体方法为:将被保护的氨基酸逐个偶联到固相树脂上,然后在强酸下将肽链从树脂上裂解同时去除侧链保护基团,具体如下:
(1)称取200mg的Wang树脂,按照上述固相多肽合成程序循环,依次加入200mg的Gly依次进行反应;待反应完成后,向管加入80mg的Asn与等量的HBTU进行偶联,待偶联完毕后,向每管分别加入90mg的Asp与等量的HBTU进行偶联;待偶联完毕后,树脂脱保护后加入60mg的Glu与等量的HBTU进行偶联;待偶联完毕后,向每管分别加入80mg的Tyr与等量的HBTU进行偶联;
(2)待偶联完毕后,向每管分别加入100mg的Tyr与等量的HBTU进行偶联;待偶联完毕后,向每管分别加入80mg的Thr与等量的HBTU进行偶联;待偶联完毕后,每Asn与等量的HBTU进行偶联;待偶联完毕后,Lys(Dde)与等量的HBTU进行偶联;待偶联完毕后,用2%水合肼将Lys的侧链保护基Dde脱掉暴露氨基后,加入四氮杂环十二烷四乙酸(DOTA)到DMF中,用DIEA调节pH值至8.5-9.0,室温搅拌过夜;加入20%哌啶脱保护,室温反应10分钟,管中加入90mg的Cys与等量的HBTU进行偶联;经过甲醇置换和收缩步骤,真空抽干,用95%TFA裂解得到的产品CK(DOTA)NTYYEDQG,粗品MALDI-TOF鉴定和HPLC纯化用于后续试验。CK(DOTA)NTYYEDQG的质谱和液相色谱检测结果如图1和图2所示,表明该多肽探针的纯度和偶连物的正确性。
实施例2 ICG-CK(DOTA)NTYYEDQG的制备
将1mg实施例1制备的CK(DOTA)NTYYEDQG多肽溶于1×PBS中,0.5mg ICG-MAL溶于500μL去离子水中,将二者混合调pH至7.4,室温振荡反应24h,冷冻干燥后进行质谱检测和HPLC纯化,得到ICG标记的CK(DOTA)NTYYEDQG。
ICG-CK(DOTA)NTYYEDQG的结构式如式(I)所示,其质谱检测结果如图3所示,证明了多肽探针的纯度和偶连物的正确性
实施例3 ICG-CK(68Ga-DOTA)NTYYEDQG的制备
将实施例2制备的ICG-CK(DOTA)NTYYEDQG溶于去离子水中;用5mL 0.1mol/L高纯度盐酸溶液淋洗锗镓(68Ge/68Ga)发生器(JSC Isotope)至EP管中,收集其中放射性含量最高的1mL,加入1.25mol/L醋酸钠100μL将混合液pH值调至3.5-4.5;将30μg前体加入至混合液中并充分混匀,加热至100℃保持10min;反应结束后将反应液冷却至室温,并加入无菌注射用水4mL后,通过无菌滤膜(0.22μm,13mm)过滤至无菌产品瓶中,得到ICG-CK(68Ga-DOTA)NTYYEDQG。
参考上述方法制备68Ga-DOTA-NTYYEDQG。
对68Ga-DOTA-NTYYEDQG的放射性进行检测:使用高效液相色谱(美国Waters公司,515型泵);紫外检测器(486型,),放射性检测器(美国EG&G BERTHOLD公司),放射性活度计CRC-25PET(美国Capintec公司),Waters色谱柱Nova-Pak C18(4.6×150mm,5μm)。上步中分析型HPLC方法如下:使用Waters HPLC系统配备Waters C18分析柱(4.6mm×250mm),流动相A为乙腈(0.1%三氟乙酸),流动相B为水(0.1%三氟乙酸),流速为1mL/min,梯度洗脱条件:0min,乙腈/水(5/95,v/v);5min,乙腈/水(5/95,v/v);10min,乙腈/水(80/20,v/v);15min,乙腈/水(100/0,v/v);18min,乙腈/水(100/0,v/v);20min,乙腈/水(5/95,v/v),洗脱剂中含有0.1%TFA,流速为1mL/min。紫外检测波长为210nm,柱温20℃。放射性检测应用HPLC专用放射性探测器。
由图4的放射性HPLC图谱中可知,68Ga-DOTA-NTYYEDQG的保留时间(RetentionTime)为11.6min,放化纯度(purity)>99%,可以作为PET探针靶向表达PD-L1的肿瘤成像。
实施例4 ICG-CK(DOTA)NTYYEDQG小动物荧光成像
将非小细胞肺癌细胞系NCI-H1975用含10%胎牛血清的RPMI1640培养基培养,按1×106通过皮下注射入Balb/c裸鼠右后肢,待肿瘤长至50mm3。称取1mg ICG-CK(DOTA)NTYYEDQG多肽溶于1mL的1×PBS中,尾静脉注射150μL的ICG-多肽半小时后,使用IVISSpectrum小动物活体光学三维成像系统进行信号采集。28h解剖后取主要器官进行体外荧光分布成像。
结果如图5所示,将上述制备得到的多肽显像制剂经尾静脉注射入PD-L1高表达的荷瘤小鼠体内,在1小时之内,肿瘤部位荧光信号逐渐增强,证明了本发明的分子探针具有PD-L1靶向性,可以实现微小肿瘤的高灵敏度活体成像。
综上所述,本发明的双模态多肽探针具有靶向表达PD-L1阳性肿瘤细胞的特性,因而在实际应用中,可以将本发明的靶向多肽探针用于肿瘤的靶向治疗和成像,实现免疫治疗反应标志物PD-L1的无创可视化检测。
虽然,上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
序列表
<110> 福建医科大学附属第一医院
<120> 一种PD-L1靶向双模态分子探针及其制备方法和应用
<130> KHP211112454.1
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 8
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Asn Thr Tyr Tyr Glu Asp Gln Gly
1 5
Claims (10)
1.一种PD-L1靶向双模态分子探针,其特征在于,其为同时由吲哚菁绿ICG和正电子放射性核素68Ga标记的多肽,所述多肽的序列如SEQ ID NO.1所示。
2.根据权利要求1所述的PD-L1靶向双模态分子探针,其特征在于,所述ICG和68Ga分别通过双功能螯合剂DOTA与所述多肽连接。
4.权利要求1~3任一项所述的PD-L1靶向双模态分子探针的衍生物,其特征在于,所述衍生物为所述双模态分子探针的二价体或多价体且能够特异性结合PD-L1;
所述二价体或多价体为二个或多个所述双模态分子探针通过连接分子共价连接形成,或者,通过与多聚体混合、非共价连接形成;
优选地,所述的连接分子为2-S-(4-氨基苯)-1,4,7三氮杂环壬烷-1,4,7-三乙酸(NOTA)、1-乙基-3-(3-二甲基氨丙基)-碳化二亚胺(EDC)或N-羟基琥珀酰亚胺(NHS);
和/或,所述多聚体为聚乙二醇(PEG)、聚乙烯醇(PVA)、环糊精、聚酰胺-胺型树枝状高分子(PAMAM)、聚乳酸(PLA)、聚乳酸-乙醇胺(PLGA)中的任意一种或至少两种的组合。
5.权利要求1~3任一项所述的PD-L1靶向双模态分子探针或权利要求4所述的衍生物在制备药物中的应用。
6.根据权利要求5所述的应用,其特征在于,所述药物为用于PD-L1阳性肿瘤的预防、诊断或治疗的药物;
优选地,所述PD-L1阳性肿瘤为选自黑色素瘤、非小细胞肺癌、肾癌、前列腺癌、结直肠癌、胰腺癌、肝癌、胃癌、食道癌和乳腺癌中的任意一种。
7.一种药物,其特征在于,包括权利要求1~3任一项所述的PD-L1靶向双模态分子探针或权利要求4所述的衍生物。
8.根据权利要求7所述的药物,其特征在于,所述药物还包括显像制剂;
优选地,所述药物中,所述双模态分子探针、其二价体或多价体与所述显像制剂相缀合或混合;
更优选地,所述的显像制剂为放射性核素、放射性核素标记物、磁共振造影剂、分子影像制剂中的任意一种。
9.权利要求1~3任一项所述的PD-L1靶向双模态分子探针的制备方法,其特征在于,包括如下步骤:将序列如SEQ ID NO.1所示的多肽与DOTA连接,得到PDP线性多肽;将所述PDP线性多肽进行ICG标记后,再进行68Ga标记。
10.根据权利要求9所述的制备方法,其特征在于,包括如下步骤:
(1)CK(DOTA)NTYYEDQG的制备
先通过Fmoc固相合成Fmoc-CK(Dde)NTYYEDQG,用2%水合肼将Lys的侧链保护基Dde脱掉暴露氨基后得到Fmoc-CKNTYYEDQG,将DOTA和Fmoc-CKNTYYEDQG多肽溶于DMF中,用DIEA调节pH值至8.5-9.0,室温搅拌过夜;加入20%哌啶脱保护,室温反应10分钟;得到的产品经C18半制备柱HPLC分离纯化,得到PDP线性多肽CK(DOTA)NTYYEDQG;
(2)ICG-CK(DOTA)NTYYEDQG的制备
将1mg CK(DOTA)NTYYEDQG多肽溶于1×PBS中,0.5mg ICG-MAL溶于500μL去离子水中,将二者混合调pH至7.4,室温振荡反应24h,冷冻干燥后进行质谱检测和HPLC纯化;
(3)ICG-CK(68Ga-DOTA)NTYYEDQG的制备
将ICG-CK(DOTA)NTYYEDQG溶于去离子水中;用5mL 0.1mol/L高纯度盐酸溶液淋洗锗镓68Ge/68Ga发生器,收集其中放射性含量最高的1mL,加入醋酸钠将混合液pH值调至3.5-4.5;将30μg前体ICG-CK(DOTA)NTYYEDQG加入至所述混合液中并充分混匀,加热至100℃保持10min,得到ICG-CK(68Ga-DOTA)NTYYEDQG。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110327819.9A CN112933249A (zh) | 2021-03-26 | 2021-03-26 | 一种pd-l1靶向双模态分子探针及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110327819.9A CN112933249A (zh) | 2021-03-26 | 2021-03-26 | 一种pd-l1靶向双模态分子探针及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112933249A true CN112933249A (zh) | 2021-06-11 |
Family
ID=76228312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110327819.9A Pending CN112933249A (zh) | 2021-03-26 | 2021-03-26 | 一种pd-l1靶向双模态分子探针及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112933249A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114573558A (zh) * | 2022-01-05 | 2022-06-03 | 四川大学华西医院 | 一种水溶性甲基苄醚衍生物、正电子核素探针、核素标记物及制备方法和应用 |
CN114805499A (zh) * | 2022-04-24 | 2022-07-29 | 中南大学湘雅医院 | 以pd-l1通路为靶点的pet分子探针及其应用 |
CN117338961A (zh) * | 2023-10-13 | 2024-01-05 | 江南大学 | 一种pd-l1靶向分子探针及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103480009A (zh) * | 2013-09-17 | 2014-01-01 | 北京肿瘤医院 | 双模态肿瘤靶向纳米粒子显像剂及其制备方法 |
CN111320675A (zh) * | 2020-03-11 | 2020-06-23 | 安徽医科大学第二附属医院 | 放射性锝标记的pd-l1靶向多肽及其制备方法与应用 |
CN112028968A (zh) * | 2019-06-04 | 2020-12-04 | 国家纳米科学中心 | 一种靶向pd-l1的多肽及其应用 |
CN112028982A (zh) * | 2019-06-04 | 2020-12-04 | 国家纳米科学中心 | 一种靶向pd-l1的共价多肽抑制剂及其制备方法和应用 |
-
2021
- 2021-03-26 CN CN202110327819.9A patent/CN112933249A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103480009A (zh) * | 2013-09-17 | 2014-01-01 | 北京肿瘤医院 | 双模态肿瘤靶向纳米粒子显像剂及其制备方法 |
CN112028968A (zh) * | 2019-06-04 | 2020-12-04 | 国家纳米科学中心 | 一种靶向pd-l1的多肽及其应用 |
CN112028982A (zh) * | 2019-06-04 | 2020-12-04 | 国家纳米科学中心 | 一种靶向pd-l1的共价多肽抑制剂及其制备方法和应用 |
CN111320675A (zh) * | 2020-03-11 | 2020-06-23 | 安徽医科大学第二附属医院 | 放射性锝标记的pd-l1靶向多肽及其制备方法与应用 |
Non-Patent Citations (5)
Title |
---|
ANDERS JOSEFSSON等: "Biodistribution, dosimetry and imaging of 225 Ac-DOTA-anti-PD-L1-BC in a murine immunocompetent transgenic breast cancer model", 《JRC PUBLICATIONS REPOSITORY》 * |
RAVINDRAA.DESILVA等: "Peptide-Based 68Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer", 《MOL.PHARMACEUTICS》 * |
SETSUKO TSUBOI等: "Shortwave-infrared(SWIR) fluorescencemolecular imaging using indocyanine green-antibody conjugates for the optical diagnostics of cancerous tumours", 《THE ROYAL SOCIETY OF CHEMISTRY》 * |
UN CHOL SHIN ETAL: "Preliminary evaluation of new 68Ga-labeled cyclic RGD peptides by PET imaging", 《JOURNAL OF RADIOPHARMACEUTICALS AND MOLECULAR PROBES》 * |
YANG DU等: "Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-64Cu/IRDye 800CW Allows Improved Breast Tumor Targeted Imaging and Therapy", 《MOL. PHARMACEUTICS》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114573558A (zh) * | 2022-01-05 | 2022-06-03 | 四川大学华西医院 | 一种水溶性甲基苄醚衍生物、正电子核素探针、核素标记物及制备方法和应用 |
CN114573558B (zh) * | 2022-01-05 | 2022-11-08 | 四川大学华西医院 | 一种水溶性甲基苄醚衍生物、正电子核素探针、核素标记物及制备方法和应用 |
CN114805499A (zh) * | 2022-04-24 | 2022-07-29 | 中南大学湘雅医院 | 以pd-l1通路为靶点的pet分子探针及其应用 |
CN117338961A (zh) * | 2023-10-13 | 2024-01-05 | 江南大学 | 一种pd-l1靶向分子探针及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112933249A (zh) | 一种pd-l1靶向双模态分子探针及其制备方法和应用 | |
Sato et al. | Role of fluorophore charge on the in vivo optical imaging properties of near-infrared cyanine dye/monoclonal antibody conjugates | |
Wang et al. | A novel plectin/integrin-targeted bispecific molecular probe for magnetic resonance/near-infrared imaging of pancreatic cancer | |
US20150202335A1 (en) | Targeted molecular imaging probe and method for in vivo molecular imaging | |
CN108623661B (zh) | 一种靶向胰腺癌肿瘤细胞的双特异性多肽分子探针及应用 | |
CN109824765B (zh) | 68Ga标记AEEA修饰c-Met分子成像探针及制备与应用 | |
US10064964B2 (en) | Compounds and methods for the detection of TRPV-6 cancers and drug delivery | |
Huang et al. | Design, synthesis and validation of integrin α 2 β 1-targeted probe for microPET imaging of prostate cancer | |
Li et al. | Near-infrared fluorescence imaging of CD13 receptor expression using a novel Cy5. 5-labeled dimeric NGR peptide | |
Zhou et al. | A novel near-infrared fluorescent probe TMTP1-PEG4-ICG for in vivo tumor imaging | |
CN110845572A (zh) | 肿瘤靶向的grp类似物及其应用 | |
CN107868129B (zh) | 与肝癌标志物gpc3相关的亲和肽 | |
EP3978033A1 (en) | Rk polypeptide radiopharmaceutical targeting her2, and preparation method therefor | |
CN113583089A (zh) | 靶向肿瘤pd-l1的pet显像剂、其标记前体、制法和应用 | |
CN112043839A (zh) | 靶向转铁蛋白受体的放射性同位素标记多肽显像剂及其应用 | |
Stammes et al. | Pre-clinical evaluation of a cyanine-based SPECT probe for multimodal tumor necrosis imaging | |
CN111675750A (zh) | 针对癌胚抗原相关黏附分子ceacam的肿瘤靶向肽及其应用 | |
CN113880917B (zh) | 几种肿瘤高亲和肽及其应用 | |
Cheng et al. | Non-invasive molecular imaging for precision diagnosis of metastatic lymph nodes: opportunities from preclinical to clinical applications | |
Pung et al. | Generation of peptides using phage display technology for cancer diagnosis and molecular imaging | |
Hernandez Vargas et al. | High-contrast detection of somatostatin receptor subtype-2 for fluorescence-guided surgery | |
Cao et al. | Novel HER2-Targeted Peptide for NIR-II Imaging of Tumor | |
CN106008339A (zh) | 一种放射性c-met靶向亲和小分子化合物及其应用 | |
CN112028968B (zh) | 一种靶向pd-l1的多肽及其应用 | |
CN116063379A (zh) | EphA2靶向多肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210611 |
|
RJ01 | Rejection of invention patent application after publication |